Effect of suppressive levothyroxine therapy on bone mineral density in young patients with differentiated thyroid carcinoma
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/254163 |
Resumo: | Suppressive levothyroxine therapy (sT4) is a cornerstone in the management of differentiated thyroid cancer (DTC). Long-term sT4 may affect bone mineral density (BMD). We evaluated the effect of sT4 on the bone mass of young DTC patients. In this cross-sectional study, BMD was evaluated via dual-energy X-ray absorptiometry in DTC patients younger than 25 years at diagnosis and undergoing sT4 for ≥1 year. The two control groups comprised patients matched for sex, age, and body-mass-index who were thyroidectomized for indications other than DTC and undergoing L-T4-replacement therapy, and healthy individuals with no prior known thyroid disease. Ninety-three participants were included (thirty-one in each group). There were no differences in the mean age, female sex (77.4% in all groups), or BMI between the sT4 group and each control group. The median TSH level was lower (0.4 [0.04–6.5] vs. 2.7 [0.8–8.5] mIU/mL, p = 0.01) and the mean L-T4 mcg/Kg levels were higher (2.4 ± 0.6 vs. 1.6 ± 0.3, p = 0.01) in the sT4 group compared to the L-T4-replacement therapy group. Lumbar spine, femoral neck, and total femur BMD were all similar among the groups. sT4 does not impact BMD in young DTC patients after a median time of suppression of 8 years. These findings may help in the decision-making and risk/benefit evaluation of sT4 for this population. |
id |
UFRGS-2_b19ba6f3a730e1ee89d55826d86a0569 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/254163 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Zanella, André BorsattoMarmitt, LauraFighera, Tayane MunizScheffel, Rafael SelbachSpritzer, Poli MaraDora, José Miguel SilvaMaia, Ana Luiza Silva2023-02-07T05:01:31Z20222218-1989http://hdl.handle.net/10183/254163001157891Suppressive levothyroxine therapy (sT4) is a cornerstone in the management of differentiated thyroid cancer (DTC). Long-term sT4 may affect bone mineral density (BMD). We evaluated the effect of sT4 on the bone mass of young DTC patients. In this cross-sectional study, BMD was evaluated via dual-energy X-ray absorptiometry in DTC patients younger than 25 years at diagnosis and undergoing sT4 for ≥1 year. The two control groups comprised patients matched for sex, age, and body-mass-index who were thyroidectomized for indications other than DTC and undergoing L-T4-replacement therapy, and healthy individuals with no prior known thyroid disease. Ninety-three participants were included (thirty-one in each group). There were no differences in the mean age, female sex (77.4% in all groups), or BMI between the sT4 group and each control group. The median TSH level was lower (0.4 [0.04–6.5] vs. 2.7 [0.8–8.5] mIU/mL, p = 0.01) and the mean L-T4 mcg/Kg levels were higher (2.4 ± 0.6 vs. 1.6 ± 0.3, p = 0.01) in the sT4 group compared to the L-T4-replacement therapy group. Lumbar spine, femoral neck, and total femur BMD were all similar among the groups. sT4 does not impact BMD in young DTC patients after a median time of suppression of 8 years. These findings may help in the decision-making and risk/benefit evaluation of sT4 for this population.application/pdfengMetabolites. Basel. Vol. 12, no. 9 (Sept. 2022), 842, 9 p.Neoplasias da glândula tireóideDensidade ósseaTireotropinaTiroxinaDifferentiated thyroid carcinomaPediatric patientsSuppressive levothyroxineBone densityEffect of suppressive levothyroxine therapy on bone mineral density in young patients with differentiated thyroid carcinomaEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001157891.pdf.txt001157891.pdf.txtExtracted Texttext/plain36356http://www.lume.ufrgs.br/bitstream/10183/254163/2/001157891.pdf.txtbf2e0bb66e802094e0052b9fbf2a107fMD52ORIGINAL001157891.pdfTexto completo (inglês)application/pdf1617764http://www.lume.ufrgs.br/bitstream/10183/254163/1/001157891.pdf83d96ac78881002e4d6bd423c13bbe97MD5110183/2541632023-06-07 03:41:00.983064oai:www.lume.ufrgs.br:10183/254163Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-06-07T06:41Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Effect of suppressive levothyroxine therapy on bone mineral density in young patients with differentiated thyroid carcinoma |
title |
Effect of suppressive levothyroxine therapy on bone mineral density in young patients with differentiated thyroid carcinoma |
spellingShingle |
Effect of suppressive levothyroxine therapy on bone mineral density in young patients with differentiated thyroid carcinoma Zanella, André Borsatto Neoplasias da glândula tireóide Densidade óssea Tireotropina Tiroxina Differentiated thyroid carcinoma Pediatric patients Suppressive levothyroxine Bone density |
title_short |
Effect of suppressive levothyroxine therapy on bone mineral density in young patients with differentiated thyroid carcinoma |
title_full |
Effect of suppressive levothyroxine therapy on bone mineral density in young patients with differentiated thyroid carcinoma |
title_fullStr |
Effect of suppressive levothyroxine therapy on bone mineral density in young patients with differentiated thyroid carcinoma |
title_full_unstemmed |
Effect of suppressive levothyroxine therapy on bone mineral density in young patients with differentiated thyroid carcinoma |
title_sort |
Effect of suppressive levothyroxine therapy on bone mineral density in young patients with differentiated thyroid carcinoma |
author |
Zanella, André Borsatto |
author_facet |
Zanella, André Borsatto Marmitt, Laura Fighera, Tayane Muniz Scheffel, Rafael Selbach Spritzer, Poli Mara Dora, José Miguel Silva Maia, Ana Luiza Silva |
author_role |
author |
author2 |
Marmitt, Laura Fighera, Tayane Muniz Scheffel, Rafael Selbach Spritzer, Poli Mara Dora, José Miguel Silva Maia, Ana Luiza Silva |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Zanella, André Borsatto Marmitt, Laura Fighera, Tayane Muniz Scheffel, Rafael Selbach Spritzer, Poli Mara Dora, José Miguel Silva Maia, Ana Luiza Silva |
dc.subject.por.fl_str_mv |
Neoplasias da glândula tireóide Densidade óssea Tireotropina Tiroxina |
topic |
Neoplasias da glândula tireóide Densidade óssea Tireotropina Tiroxina Differentiated thyroid carcinoma Pediatric patients Suppressive levothyroxine Bone density |
dc.subject.eng.fl_str_mv |
Differentiated thyroid carcinoma Pediatric patients Suppressive levothyroxine Bone density |
description |
Suppressive levothyroxine therapy (sT4) is a cornerstone in the management of differentiated thyroid cancer (DTC). Long-term sT4 may affect bone mineral density (BMD). We evaluated the effect of sT4 on the bone mass of young DTC patients. In this cross-sectional study, BMD was evaluated via dual-energy X-ray absorptiometry in DTC patients younger than 25 years at diagnosis and undergoing sT4 for ≥1 year. The two control groups comprised patients matched for sex, age, and body-mass-index who were thyroidectomized for indications other than DTC and undergoing L-T4-replacement therapy, and healthy individuals with no prior known thyroid disease. Ninety-three participants were included (thirty-one in each group). There were no differences in the mean age, female sex (77.4% in all groups), or BMI between the sT4 group and each control group. The median TSH level was lower (0.4 [0.04–6.5] vs. 2.7 [0.8–8.5] mIU/mL, p = 0.01) and the mean L-T4 mcg/Kg levels were higher (2.4 ± 0.6 vs. 1.6 ± 0.3, p = 0.01) in the sT4 group compared to the L-T4-replacement therapy group. Lumbar spine, femoral neck, and total femur BMD were all similar among the groups. sT4 does not impact BMD in young DTC patients after a median time of suppression of 8 years. These findings may help in the decision-making and risk/benefit evaluation of sT4 for this population. |
publishDate |
2022 |
dc.date.issued.fl_str_mv |
2022 |
dc.date.accessioned.fl_str_mv |
2023-02-07T05:01:31Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/254163 |
dc.identifier.issn.pt_BR.fl_str_mv |
2218-1989 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001157891 |
identifier_str_mv |
2218-1989 001157891 |
url |
http://hdl.handle.net/10183/254163 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Metabolites. Basel. Vol. 12, no. 9 (Sept. 2022), 842, 9 p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/254163/2/001157891.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/254163/1/001157891.pdf |
bitstream.checksum.fl_str_mv |
bf2e0bb66e802094e0052b9fbf2a107f 83d96ac78881002e4d6bd423c13bbe97 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801225079662575616 |